Real-world data confirm benefit and safety of ANT-DBS for drug-resistant epilepsy

Real-world data have confirmed the benefit and safety of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) in patients with drug-resistant epilepsy (DRE), according to new findings presented at the EAN 2021 virtual conference.

With the efficacy and safety of ANT-DBS demonstrated in the double-blind randomized controlled SANTE trial, researchers set out to evaluate the longer-term effects when used in routine clinical practice.